Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study - Report - MDSpire

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study

  • By

  • Stefan M. Kahnert

  • Lara Jürgens

  • Leonie Dreher

  • Christian Schmidt-Lauber

  • Ansgar Koechel

  • Gina L. Frank

  • Tobias B. Huber

  • Meike Shedden-Mora

  • Sonja Ständer

  • Markus Ramm

  • Gudrun Schneider

  • Rupert Conrad

  • June 16, 2026

  • 0 min

Share

Link Between suPAR Inflammatory Marker and Chronic Pruritus of Unidentified Cause

Overview

The SOMA.PRU study reveals that patients with chronic pruritus of unknown origin (CPUO) exhibit significantly higher serum levels of the inflammatory marker suPAR compared to those with chronic atopic dermatitis. This suggests a potential role of systemic inflammation in the pathophysiology of CPUO.

Background

Chronic pruritus is a common and debilitating symptom affecting a significant portion of the population, often leading to decreased quality of life. Understanding the underlying mechanisms, particularly the role of systemic inflammation, is crucial for developing effective treatments. The soluble urokinase plasminogen activator receptor (suPAR) has emerged as a promising biomarker for chronic inflammation, yet its relationship with chronic pruritus remains underexplored.

Data Highlights

GroupsuPAR Levels (ng/ml)
CPUO3.2 ± 2.5
Controls2.9 ± 1.1
cAD2.0 ± 0.9

Key Findings

  • Patients with CPUO had the highest suPAR levels compared to controls and cAD.
  • suPAR levels in CPUO were significantly higher than in cAD (p = 0.018).
  • Higher baseline suPAR levels in CPUO correlated with increased pruritus intensity at follow-up.
  • Chronic systemic inflammation may play a significant role in the pathophysiology of CPUO.
  • suPAR could serve as a potential biomarker for monitoring the clinical course of CPUO.

Clinical Implications

The findings suggest that measuring suPAR levels may help in understanding the inflammatory status of patients with CPUO, potentially guiding treatment strategies. Clinicians should consider the role of systemic inflammation in managing chronic pruritus, particularly when the underlying cause is unclear.

Conclusion

This study highlights the association between systemic inflammation and chronic pruritus of unknown origin, suggesting that suPAR may be a valuable biomarker for this condition. Further research is warranted to explore its clinical utility.

Related Resources & Content

  1. SOMA.PRU Study, Dermatology and Therapy, 2023 -- Link Between suPAR and Chronic Pruritus
  2. Beyond the Skin: Assessing Itch in Atopic Dermatitis, Dermatology and Therapy, 2023 -- Insights from UK Dermatologists
  3. Spinal and supraspinal mechanisms of chronic itch, Frontiers in Medicine, 2026 -- from neuronal circuits to the neuro-immune-microbial axis
  4. Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis, Dermatology and Therapy, 2023
  5. European Guideline on Chronic Pruritus, 2025
  6. The New Gastroenterologist — Linerixibat Alleviates Pruritus in Patients with Primary Biliary Cholangitis
  7. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
  8. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) as a Biomarker of Neurodysfunction
  9. European Guideline on Chronic Pruritus

Original Source(s)

Related Content